Avidity Biosciences, INC Form 4 insider transactions

Husam Younis, Chief Scientific Officer of Atrium Therapeutics, Inc., reported a transaction in 11,216 shares of common stock on September 18, 2026.

Steven George Hughes, Chief Medical Officer of Atrium Therapeutics, Inc., reported a transaction in 21,459 shares of common stock on September 18, 2026.

W. Michael Flanagan, a Director of Atrium Therapeutics, Inc., reported a transaction in 22,812 shares of common stock on September 18, 2026.

Sarah Boyce, a Director of Atrium Therapeutics, Inc., reported a transaction in 126,418 shares of common stock on September 18, 2026.

Stephanie Kenney, See Remarks of Atrium Therapeutics, Inc., reported a transaction in 2,375 shares of common stock on September 18, 2026.

Kathleen P. Gallagher, See Remarks and a Director of Atrium Therapeutics, Inc., reported a transaction in 11,632 shares of common stock on September 18, 2026.

Brendan R. Winslow, Chief Financial Officer of Atrium Therapeutics, Inc., reported a transaction in 6,742 shares of common stock on September 18, 2026.

Avidity Biosciences' Chief Human Resources Officer, Teresa McCarthy, disposed of common stock and stock options following the merger agreement with Novartis AG.

Avidity Biosciences director Tamar Thompson disposed of common stock and stock options on February 27, 2026, as part of the previously announced merger agreement with Novartis AG.

Avidity Biosciences' CFO, Michael F. MacLean, disposed of all common stock and stock options following the company's acquisition by Novartis AG.

Avidity Biosciences Director Simona Skerjanec disposed of all her common stock and stock options as part of the merger agreement with Novartis AG.

Avidity Biosciences' Chief Medical Officer disposed of all common stock and stock options following the company's acquisition by Novartis AG for $72.00 per share.

Avidity Biosciences' President and CEO, Sarah Boyce, disposed of all her common stock and stock options as part of the acquisition by Novartis AG.

Avidity Biosciences' Chief Legal Officer, John B. Moriarty, disposed of common stock and stock options as part of the previously announced merger with Novartis.

Avidity Biosciences' Chief Scientific Officer, W. Michael Flanagan, disposed of common stock and stock options as part of the previously announced merger with Novartis.

Avidity Biosciences Director Troy Edward Wilson disposed of all his common stock and stock options as part of the previously announced merger with Novartis at $72.00 per share.

Avidity Biosciences' Chief Program Officer, Kathleen P. Gallagher, disposed of all her common stock and stock options as part of the merger agreement with Novartis AG.

Avidity Biosciences director Noreen Henig disposed of all common stock and stock options as part of the company's acquisition by Novartis AG for $72.00 per share.

Avidity Biosciences Director Jean Jinsun Kim disposed of common stock and stock options on February 27, 2026, as part of the previously announced merger with Novartis AG.

Avidity Biosciences director Arthur A. Levin disposed of all his common stock and stock options as part of the previously announced merger with Novartis AG.

Avidity Biosciences Director Edward M. Kaye disposed of common stock and stock options as part of the previously announced merger with Novartis AG.

Avidity Biosciences Director Carsten Boess disposed of common stock and stock options on February 27, 2026, as part of the previously announced merger with Novartis AG.

Avidity Biosciences' Chief Commercial Officer, Eric Mosbrooker, disposed of common stock and stock options as part of the previously announced merger with Novartis AG.

Avidity Biosciences' Chief Technical Officer, Charles Calderaro III, disposed of common stock and stock options on February 27, 2026, as part of the previously announced merger agreement with Novartis AG.

Avidity Biosciences' Chief Medical Officer, Steven George Hughes, reported a non-discretionary sale of common stock totaling 4,895 shares to cover tax withholding obligations related to RSU vesting.

Avidity Biosciences' President and CEO, Sarah Boyce, sold 14,387 shares of common stock at $72.45 per share to cover tax withholding obligations related to RSU vesting.

Avidity Biosciences' Chief Scientific Officer, W. Michael Flanagan, sold shares to cover tax withholding obligations related to RSU vesting.

Avidity Biosciences' CFO, Michael F. MacLean, sold 4,542 shares of common stock at $72.45 per share to cover tax withholding obligations related to RSU vesting.

Avidity Biosciences director Arthur A. Levin sold 1,758 shares of common stock in a non-discretionary transaction to cover tax withholding obligations.

Avidity Biosciences' Chief Human Resources Officer, Teresa McCarthy, executed a non-discretionary 'sell-to-cover' transaction to satisfy tax withholding obligations related to RSU vesting.